425: Reneo Pharmaceuticals and OnKure Announce Proposed Merger to Create Oncology-Focused Biopharmaceutical Company

Reneo Pharmaceuticals and OnKure, Inc. have announced a definitive merger agreement to create a Nasdaq-listed biopharmaceutical company focused on advancing OnKure's portfolio of precision medicines in oncology.

Summary

• Reneo Pharmaceuticals and OnKure, Inc. have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
• The combined company will focus on advancing OnKure's pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3K), including its lead program OKI-219.
• Upon completion, the combined company is expected to operate under the name OnKure Therapeutics, Inc., and trade on the Nasdaq Global Market under the ticker symbol OKUR.
• Reneo Pharmaceuticals has entered into a subscription agreement for a $65 million private investment in public equity (PIPE) financing expected to close concurrently with the merger.
• Pre-merger OnKure stockholders are expected to own approximately 69% of the combined company, and pre-merger Reneo stockholders are expected to own approximately 31% of the combined company, exclusive of the PIPE financing.
• The combined company is expected to have approximately $120 million of cash resources at closing, which is expected to provide funding through multiple clinical milestones and runway into the fourth quarter of 2026.
• The merger and concurrent PIPE financing are expected to close in 2024, subject to customary closing conditions, including approval by the stockholders of each company.
• Following the merger, the combined company will be led by Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure, and other members of the OnKure management team.
• The board of directors of the combined company will be composed of eight members, including six board members chosen by OnKure and two members from the legacy Reneo board.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. The merger and PIPE financing provide the combined company with resources to advance its pipeline, but the success of the venture depends on the clinical development and regulatory approval of OnKure's product candidates.

Positives

• The merger creates a company focused on precision medicines in oncology, a high-growth area.
• The combined company will have sufficient cash to fund operations through multiple clinical milestones.
• OnKure's lead program, OKI-219, has the potential to become a meaningful treatment option for patients suffering from breast cancer.
• The merger brings together an experienced team of drug developers from both companies.

Negatives

• The merger is subject to stockholder approval and other customary closing conditions, which could delay or prevent the transaction from closing.
• The combined company will be reliant on the success of OnKure's pipeline candidates, which are still in early stages of development.
• Reneo stockholders will experience significant dilution as a result of the merger and PIPE financing.

Risks

• The conditions to the closing of the Proposed Transactions are not satisfied, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions.
• Uncertainties as to the timing of the closing of the Proposed Transactions and the ability of each of Reneo and OnKure to consummate the Proposed Transactions.
• Risks related to the ability of Reneo and OnKure to correctly estimate and manage their respective operating expenses and expenses associated with the Proposed Transactions pending the closing of the Proposed Transactions.
• Risks associated with the possible failure to realize certain anticipated benefits of the Proposed Transactions, including with respect to future financial and operating results.
• The potential for, and uncertainty associated with the outcome of, any legal proceedings that may be instituted against Reneo or OnKure or any of their respective directors or officers related to the Proposed Transactions.
• Risks related to OnKures early stage of development.
• The uncertainties associated with OnKures product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials.
• The requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all.

Future Outlook

The combined company is expected to have sufficient cash to fund operations into the fourth quarter of 2026 and through multiple clinical data reports. The merger and concurrent PIPE financing are expected to close in 2024.

Management Comments

• Mike Grey, Executive Chairman and founder of Reneo Pharmaceuticals, stated that the anticipated transaction represents a compelling opportunity to deliver shareholder value as the OnKure team advances their PI3K inhibitors.
• Nicholas Saccomano, President and Chief Executive Officer of OnKure, stated that the proposed merger with Reneo Pharmaceuticals will allow them to create a publicly traded company focused on advancing OnKures lead, mutant-specific programs targeting PI3K in breast cancer.

Industry Context

The announcement reflects a trend in the biopharmaceutical industry towards mergers and acquisitions to consolidate pipelines and resources, particularly in the competitive oncology space. The focus on precision medicines targeting specific oncogenic mutations aligns with the industry's shift towards personalized therapies.

Comparison to Industry Standards

• The focus on PI3K inhibitors places the combined company in a competitive landscape with other companies developing similar therapies, such as Roche (Inavolisib) and Relay Therapeutics.
• The emphasis on mutant selectivity is a key differentiator, as existing PI3K inhibitors like Alpelisib have limitations due to on-target toxicities.
• The $120 million cash position is comparable to other clinical-stage biopharmaceutical companies and should provide sufficient runway to reach key clinical milestones.

Management Changes

Corporate Governance

Legal Proceedings

• The potential for, and uncertainty associated with the outcome of, any legal proceedings that may be instituted against Reneo or OnKure or any of their respective directors or officers related to the Proposed Transactions.

Stakeholder Impact

• Reneo stockholders will experience dilution but may benefit from the potential upside of OnKure's pipeline.
• OnKure stockholders will gain access to the public markets and additional capital to advance their programs.
• Employees of both companies may experience uncertainty during the integration process.
• Patients may benefit from the development of new precision medicines for cancer.

Next Steps

• Reneo and OnKure will seek stockholder approval for the proposed transactions.
• Reneo will file a registration statement on Form S-4 with the SEC.
• The companies will work to satisfy customary closing conditions and close the merger and PIPE financing in 2024.
• OnKure will continue to advance its PIKture-01 trial and expects early clinical data in the fourth quarter of this year.

Key Dates